MedTrace Logo

Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer

NCT00577057 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 798

Last updated 2013-08-22

No results posted yet for this study

Summary

The objectives of this clinical study are threefold:

1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant chemotherapy to radiation.
2. To test whether replacing fluorouracil with Xeloda in combining with cisplatin (PF or PX, respectively) in the chemotherapy plan will maintain or improve further the chemotherapy benefits while reducing the duration of hospital stay.
3. To see if accelerated fractionation radiotherapy can improve the outcome of patients as compared with conventional fractionation radiotherapy.

Conditions

  • Nasopharyngeal Neoplasms

Interventions

PROCEDURE

Conventional Radiotherapy

PROCEDURE

Accelerated Radiotherapy

DRUG

Cisplatin

DRUG

5-fluorouracil

DRUG

Capecitabine

Sponsors & Collaborators

  • Hong Kong Nasopharyngeal Cancer Study Group Limited

    collaborator OTHER

  • Hospital Authority, Hong Kong

    lead OTHER_GOV

Principal Investigators

  • Anne WM Lee, Cos · Clinical Oncology, Pamela Youde Nethersole Eastern Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2013-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00577057 on ClinicalTrials.gov